Advertisement
Screener

ASTRAZENECA PLC (AZN) Form 6-K: Report of foreign private issuer, 2021

2.4 / 5 stars · 19/40 Roast Me

Add as a preferred source on Google

ASTRAZENECA PLC Form 6-K: Report of foreign private issuer

Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.

  • 2021-12-29: Form 6-K; Period of report 2021-12-29; Description ASTRAZENECA AND IONIS CLOSE EPLONTERSEN DEAL; Document a8637w.htm.
  • 2021-12-21: Form 6-K; Period of report 2021-12-21; Description ULTOMIRIS ACCEPTED FOR FDA PRIORITY REVIEW FOR GMG; Document a3211w.htm.
  • 2021-12-20: Form 6-K; Period of report 2021-12-20; Description TEZSPIRE APPROVED IN THE US FOR SEVERE ASTHMA; Document a1228w.htm.
  • 2021-12-20: Form 6-K; Period of report 2021-12-20; Description SAPHNELO RECOMMENDED FOR EU APPROVAL FOR SLE; Document a1226w.htm.
FiledFormPeriod of reportDescriptionDocument
2021-12-296-K2021-12-29ASTRAZENECA AND IONIS CLOSE EPLONTERSEN DEALa8637w.htm
2021-12-216-K2021-12-21ULTOMIRIS ACCEPTED FOR FDA PRIORITY REVIEW FOR GMGa3211w.htm
2021-12-206-K2021-12-20TEZSPIRE APPROVED IN THE US FOR SEVERE ASTHMAa1228w.htm
2021-12-206-K2021-12-20SAPHNELO RECOMMENDED FOR EU APPROVAL FOR SLEa1226w.htm
2021-12-156-K2021-12-15DIRECTOR/PDMR SHAREHOLDINGa7760v.htm
2021-12-096-K2021-12-09EVUSHELD US FDA EUAa0538v.htm
2021-12-076-K2021-12-07ASTRAZENECA, IONIS TO COLLABORATE ON EPLONTERSENa8026u.htm
2021-12-016-K2021-12-01BLOCK LISTING INTERIM REVIEWa2430u.htm
2021-12-016-K2021-12-01TOTAL VOTING RIGHTSa2422u.htm
2021-11-306-K2021-11-30LYNPARZA GRANTED FDA PRIORITY REVIEW FOR OLYMPIAa0056u.htm
2021-11-156-K2021-11-15DIRECTOR/PDMR SHAREHOLDINGa4338s.htm
2021-11-126-K2021-11-12AZN: YEAR TO DATE AND Q3 2021 RESULTSa1635s.htm
2021-11-016-K2021-11-01TOTAL VOTING RIGHTSa9316q.htm
2021-11-016-K2021-11-01ASTRAZENECA TO TRANSFER RIGHTS TO EKLIRA, DUAKLIRa8147q.htm
2021-10-256-K2021-10-25IMFINZI IMPROVED SURVIVAL IN BILIARY TRACT CANCERa1084q.htm
2021-10-186-K2021-10-18AZ RECOMMENDS ADS HOLDERS REJECT MINI-TENDER OFFERa3084p.htm
2021-10-156-K2021-10-15IMFINZI & TREMELIMUMAB IMPROVED OS IN LIVER CANCERa2140p.htm
2021-10-126-K2021-10-12AZD7442 PHIII TRIAL POSITIVE IN COVID OUTPATIENTSa5796o.htm
2021-10-046-K2021-10-04ENHERTU GRANTED BTD FOR BREAST CANCERa8765n.htm
2021-10-016-K2021-10-01TOTAL VOTING RIGHTSa7798n.htm
2021-09-306-K2021-09-30DIRECTOR/PDMR SHAREHOLDINGa6036n.htm
2021-09-296-K2021-09-29ASTRAZENECA TO FULLY ACQUIRE CAELUM BIOSCIENCESa3486n.htm
2021-09-286-K2021-09-28SAPHNELO APPROVED IN JAPAN FOR SLEa1891n.htm
2021-09-246-K2021-09-24LYNPARZA PROPEL TRIAL MEETS PRIMARY ENDPOINTa8809m.htm
2021-09-236-K2021-09-23BOARD COMMITTEE CHANGEa6850m.htm
2021-09-236-K2021-09-23NEW SUSTAINABILITY COMMITTEE OF THE BOARDa6848m.htm
2021-09-216-K2021-09-21ASTRAZENECA $360M IRISH MANUFACTURING INVESTMENTa4294m.htm
2021-09-206-K2021-09-20ENHERTU REDUCED RISK OF DISEASE PROGRESSION BY 72%a2736m.htm
2021-09-096-K2021-09-09IMFINZI IMPROVES SURVIVAL IN NSCLC IN POSEIDONa3102l.htm
2021-09-096-K2021-09-09FIXED-DOSE COMBINATION OF ALBUTEROL AND BUDESONIDE (PT027) DEMONSTRATED SIGNIFICa2440l.htm
2021-09-036-K2021-09-03ULTOMIRIS APPROVED IN EU FOR CHILDREN WITH PNHa6165k.htm
2021-09-016-K2021-09-01TOTAL VOTING RIGHTSa4065k.htm
2021-08-266-K2021-08-26FORXIGA APPROVED IN JAPAN FOR CKDa8636j.htm
2021-08-266-K2021-08-26ALXN1840 WILSON PHASE III MET PRIMARY ENDPOINTa8630j.htm
2021-08-206-K2021-08-20UPDATE ON ULTOMIRIS PHASE III ALS TRIALa2935j.htm
2021-08-206-K2021-08-20AZD7442 PROPHYLAXIS TRIAL MET PRIMARY ENDPOINTa2930j.htm
2021-08-166-K2021-08-16DIRECTOR/PDMR SHAREHOLDINGa7837i.htm
2021-08-116-K2021-08-11UPDATE ON US REVIEW OF ROXADUSTATa3440i.htm
2021-08-096-K2021-08-09FORXIGA APPROVED IN THE EU FOR CKDa9764h.htm
2021-08-096-K2021-08-09ENHERTU HEAD-TO-HEAD TRIAL MEETS PRIMARY ENDPOINTa9754h.htm
2021-08-026-K2021-08-02TOTAL VOTING RIGHTSa2784h.htm
2021-08-026-K2021-08-02SAPHNELO APPROVED IN THE US FOR SLEa2087h.htm
2021-07-306-K/A2021-06-30FORM 6-K/Aazn-20210630x6ka.htm
2021-07-306-K2021-06-30FORM 6-Ktmb-20210630x6k.htm
2021-07-266-K2021-07-26ULTOMIRIS RECOMMENDED IN EU FOR CHILDREN WITH PNHa3696g.htm
2021-07-226-K2021-07-22DIRECTORATE CHANGEa0403g.htm
2021-07-216-K2021-07-21DIRECTOR/PDMR SHAREHOLDINGa0336g.htm
2021-07-216-K2021-07-21TOTAL VOTING RIGHTSa0317g.htm
2021-07-216-K2021-07-21ACQUISITION OF ALEXION COMPLETEDa0164g.htm
2021-07-216-K2021-07-21FORM 6-Ktm2122619d1_6k.htm
2021-07-196-K2021-07-19IMFINZI APPROVED IN CHINA FOR EXTENSIVE-STAGE SCLCa5875f.htm
2021-07-166-K2021-07-16STATUS ON US FDA ADVISORY COMMITTEE FOR ROXADUSTATa4525f.htm
2021-07-146-K2021-07-14ASTRAZENECA-ALEXION TRANSACTION CLEARED IN THE UKa1925f.htm
2021-07-086-K2021-07-08TEZEPELUMAB GRANTED FDA PRIORITY REVIEW FOR ASTHMAa5425e.htm
2021-07-066-K2021-07-06ASTRAZENECA-ALEXION TRANSACTION CLEARED IN THE EUa2433e.htm
2021-07-016-K2021-07-01TOTAL VOTING RIGHTSa8899d.htm
2021-06-286-K2021-06-28FORXIGA RECOMMENDED IN EU FOR PATIENTS WITH CKDa2398d.htm
2021-06-286-K2021-06-28NIRSEVIMAB PHII/III TRIAL CONFIRMS SAFETY PROFILEa2403d.htm
2021-06-246-K2021-06-24LYNPARZA APPROVED IN CHINA FOR PROSTATE CANCERa9237c.htm
2021-06-236-K2021-06-23ORPATHYS APPROVED IN CHINA FOR LUNG CANCERa8164c.htm
2021-06-226-K2021-06-22KOSELUGO APPROVED IN THE EU FOR CHILDREN WITH NF1a6686c.htm
2021-06-156-K2021-06-15UPDATE ON AZD7442 STORM CHASER TRIALa9137b.htm
2021-06-076-K2021-06-07CALQUENCE HEAD-TO-HEAD RESULTS VERSUS IBRUTINIBa9573a.htm
2021-06-046-K2021-06-04LYNPARZA REDUCED RECURRENCE RISK IN BREAST CANCERa8050a.htm
2021-06-046-K2021-06-04ASTRAZENECA APPOINTS NEW CHIEF FINANCIAL OFFICERa7959a.htm
2021-06-026-K2021-06-02PUBLICATION OF FINAL TERMSa5018a.htm
2021-06-016-K2021-06-01BLOCK LISTING INTERIM REVIEWa4476a.htm
2021-06-016-K2021-06-01TOTAL VOTING RIGHTSa4275a.htm
2021-05-286-K2021-05-28TAGRISSOAPPROVED IN THE EU FOR THE ADJUVANT TREATMENT OFPATIENTS WITH EARLY-STAGa1176a.htm
2021-05-286-K2021-05-28FORM 6-Ktm2116866d11_6k.htm
2021-05-276-K2021-05-27ASTRAZENECA PRICES A EUR800M BOND OFFERINGa0103a.htm
2021-05-266-K2021-05-26ASTRAZENECA PRICES A $7BN BOND OFFERINGa8113z.htm
2021-05-266-K2021-05-26FORM 6-Ktm2116866d9_6k.htm
2021-05-256-K2021-05-25EMTN PROGRAMME UPDATE - PUBLICATION OF PROSPECTUSa6599z.htm
2021-05-246-K2021-05-24FORM 6-Ktm2116866d3_6k.htm
2021-05-216-K2021-05-21ASTRAZENECA COVID-19 VACCINE VAXZEVRIA AUTHORISED FOR EMERGENCY USE IN JAPANa4139z.htm
2021-05-186-K2021-05-18DIRECTOR/PDMR SHAREHOLDINGa0388z.htm
2021-05-116-K2021-05-11RESULT OF AGMa2668y.htm
2021-05-116-K2021-05-11SHAREHOLDERS VOTE IN FAVOUR OF ALEXION ACQUISITIONa2664y.htm
2021-05-076-K2021-05-07IMFINZI + TREMELIMUMAB SHOWED SURVIVAL IN POSEIDONa8587x.htm
2021-05-046-K2021-05-04TOTAL VOTING RIGHTSa4839x.htm
2021-05-046-K2021-05-04FARXIGA APPROVED IN THE US FOR CKDa3382x.htm
2021-04-306-K2021-04-30AZN: FIRST QUARTER 2021 RESULTSa1438x.htm
2021-04-266-K2021-04-26NIRSEVIMAB PHASE III TRIAL MET PRIMARY ENDPOINTa5154w.htm
2021-04-266-K2021-04-26TAGRISSO ADJUVANT RECEIVES POSITIVE CHMP OPINIONa5151w.htm
2021-04-266-K2021-04-26SELUMETINIB RECOMMENDED FOR EU APPROVAL IN NF1a5149w.htm
2021-04-166-K2021-04-16US CLEARANCE OF PROPOSED ACQUISITION OF ALEXIONa7585v.htm
2021-04-146-K2021-04-14TAGRISSO APPROVED IN CHINA IN EARLY LUNG CANCERa4184v.htm
2021-04-126-K2021-04-12CIRCULAR AND NOTICE OF GENERAL MEETINGa1753v.htm
2021-04-126-K2021-04-12UPDATE ON FARXIGA COVID-19 DARE-19 PHASE III TRIALa1078v.htm
2021-04-126-K2021-04-12FORM 6-Ktm216588d5_6k.htm
2021-04-016-K2021-04-01TOTAL VOTING RIGHTSa3218u.htm
2021-03-306-K2021-03-30NOTICE OF AGMa9675t.htm
2021-03-306-K2021-03-30FORM 6-Ktm2111134d1_6k.htm
2021-03-256-K2021-03-25DIRECTOR/PDMR SHAREHOLDINGa5371t.htm
2021-03-256-K2021-03-25AZD1222 US PH3 PRIMARY ANALYSIS CONFIRMS EFFICACYa4645t.htm
2021-03-226-K2021-03-22ASTRAZENECA US VACCINE TRIAL MET PRIMARY ENDPOINTa9976s.htm
2021-03-166-K2021-03-16DIVESTMENT OF VIELA SHAREHOLDING COMPLETEDa3829s.htm
2021-03-166-K2021-03-16US SUPPLY AGREEMENT FOR ADDITIONAL AZD7442 DOSESa3832s.htm
2021-03-096-K2021-03-09DIRECTOR/PDMR SHAREHOLDINGa6865r.htm
Advertisement